发明名称 Fused thiazin-3-ones as KCA3.1 inhibitors
摘要 The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim 1, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use.;
申请公布号 US9533999(B2) 申请公布日期 2017.01.03
申请号 US201314434671 申请日期 2013.06.12
申请人 Boehringer Ingelheim International GmbH 发明人 Burke Michael J.;McKibben Bryan;Tschantz Matt Aaron
分类号 C07D513/04 主分类号 C07D513/04
代理机构 代理人 Morris Michael P.;Royaee Atabak R.
主权项 1. A compound of formula (I) wherein ring A  is fused to the 1,1-dioxothiazinone ring and chosen from L is a bond or —(CH2)n— wherein one or more methylene hydrogens is optionally replaced by C1-5alkyl, C2-6alkenyl, C2-6alkynyl or C1-5haloalkyl; n is 1 to 3; Ar is aryl or heteroaryl substituted independently by one or more halogen, C1-6haloalkyl, C1-6haloalkoxy or C1-6haloalkylS(O)m— and Ar is optionally further substituted by C1-6alkyl; m is 0, 1 or 2; each R1, R2 and R3 are independently chosen from hydrogen, halogen, C1-5alkyl, C3-6cycloalkyl, C1-5alkyl-OH, —C(O)OR4, —C(O)NR4R4, C2-6alkenyl, C2-6alkynyl, C1-5haloalkyl, —OR4 —NR4R4, —CN, —SR4, —S(O)2R4, —S(O)2NR4R4, —NHC(O)R4 and —N(C1-4alkyl)C(O)OR4; each R4 is independently hydrogen, or C1-6alkyl; or a pharmaceutically acceptable salt thereof.
地址 Ingelheim am Rhein DE